Abbott Laboratories $ABT Stock Position Raised by Financial & Tax Architects LLC

Key Points

• Financial & Tax Architects LLC increased its Abbott Laboratories stake by 25.3% in the second quarter to 80,248 shares valued at approximately $7.28 million. Institutional investors collectively own 75.18% of the company.
• Abbott exceeded quarterly expectations, reporting $1.31 in EPS and $12.59 billion in revenue, with sales up 13% year over year. Management issued third-quarter EPS guidance of $1.38–$1.46 and full-year guidance of $5.45–$5.60.
• Analysts maintain a broadly positive outlook, with a “Moderate Buy” consensus rating and an average price target of $118.67; Abbott also pays a $0.63 quarterly dividend, yielding about 2.2%. However, recent infant-formula litigation settlements, including a roughly $670 million agreement, remain a significant risk.

Financial & Tax Architects LLC increased its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 25.3% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 80,248 shares of the healthcare product maker's stock after acquiring an additional 16,198 shares during the quarter. Abbott Laboratories makes up 1.5% of Financial & Tax Architects LLC's holdings, making the stock its 21st largest holding. Financial & Tax Architects LLC's holdings in Abbott Laboratories were worth $7,282,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also modified their holdings of the stock. MidAtlantic Capital Management Inc. purchased a new position in Abbott Laboratories in the 4th quarter worth about $25,000. Cornerstone Financial Management LLC purchased a new stake in Abbott Laboratories during the fourth quarter valued at about $25,000. Purpose Unlimited Inc. purchased a new stake in Abbott Laboratories during the fourth quarter valued at about $25,000. Portfolio Resources Advisor Group Inc. acquired a new position in shares of Abbott Laboratories in the fourth quarter worth about $26,000. Finally, Abound Financial LLC purchased a new position in shares of Abbott Laboratories in the fourth quarter worth approximately $26,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Price Performance

NYSE ABT opened at $114.16 on Friday. The company has a market cap of $197.54 billion, a P/E ratio of 36.94, a P/E/G ratio of 2.21 and a beta of 0.59. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The company has a fifty day simple moving average of $99.51 and a 200 day simple moving average of $99.93.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts' consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. During the same quarter in the previous year, the business earned $1.26 EPS. The business's revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, sell-side analysts predict that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were paid a $0.63 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. Abbott Laboratories's dividend payout ratio (DPR) is presently 81.55%.

Wall Street Analysts Forecast Growth

ABT has been the subject of several research analyst reports. UBS Group reduced their price target on shares of Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating for the company in a research report on Tuesday, July 28th. Robert W. Baird began coverage on Abbott Laboratories in a report on Wednesday, July 1st. They issued an "outperform" rating and a $121.00 target price for the company. The Goldman Sachs Group decreased their target price on Abbott Laboratories from $121.00 to $113.00 and set a "buy" rating for the company in a research report on Wednesday, May 27th. Wells Fargo & Company raised their price objective on Abbott Laboratories from $109.00 to $112.00 and gave the stock an "overweight" rating in a research report on Friday, July 17th. Finally, Citigroup upped their target price on Abbott Laboratories from $108.00 to $112.00 and gave the company a "buy" rating in a report on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, Abbott Laboratories has an average rating of "Moderate Buy" and a consensus target price of $118.67.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott’s Instinct continuous glucose sensor is now integrated into MiniMed’s Flex automated insulin-delivery system, which is commercially shipping in the United States. The partnership expands Abbott’s presence in the growing continuous glucose-monitoring and diabetes-care markets. MiniMed Ships MiniMed Flex With Abbott’s Smallest Instinct Sensor
• Positive Sentiment: Abbott entered a multiyear agreement with HealthTab to supply Afinion 2 analyzers for point-of-care HbA1c and lipid testing in UK pharmacies, supporting the Diagnostics segment and potential NHS-linked distribution. HealthTab Enters Multi-Year Collaboration Agreement with Abbott
• Positive Sentiment: Analyst commentary continues to identify electrophysiology, continuous glucose-monitoring adoption and Abbott’s cardiovascular pipeline as important long-term growth drivers for the Medical Devices business. Abbott’s Medical Devices Growth Catalyst
• Neutral Sentiment: Recent commentary remains broadly constructive on Abbott’s long-term outlook, although one analysis characterized the stock as reasonably valued after its recent advance while another recommended a more cautious stance. This suggests valuation could limit near-term upside despite favorable operating trends.
• Negative Sentiment: Abbott agreed to pay approximately $670 million to resolve the Gill case and claims involving about 2,000 individuals concerning specialty formulas for premature infants. Although the company maintains that the products are safe and denies reliable evidence linking them to necrotizing enterocolitis, the settlement creates a substantial financial cost and keeps litigation risk in focus. Abbott Agrees to $670 Million Settlement
• Negative Sentiment: The company also settled an appeal related to a separate $495 million infant-formula verdict, reinforcing investor concerns about potential legal expenses and liabilities in the Nutrition business. Abbott Settles Appeal Over $495 Million Infant Formula Verdict

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source